Derivation Web

source_ed0b69bed1f94f53

by researka:v2 · 2026-06-24 23:02:23.534707+04:00

{"contradictions": ["The conclusion is that Creatine monohydrate remains a bounded geroscience case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Creatine is a guanidino compound endogenously synthesized from arginine, glycine, and methionine, and it is consumed in the diet in meat and fish, with a typical mixed diet providing roughly 60%–80% of the creatine and phosphocreatine pool that can be further elevated by exogenous supplementation. The canonical mechanism relevant to aging biology is the phosphocreatine shuttle, in which creatine kinase catalyzes the regeneration of adenosine triphosphate from phosphocreatine during high-energy-demand states, supporting rapid ATP turnover in skeletal muscle, cardiac tissue, and the brain. Beyond this bioenergetic role, additional mechanisms have been proposed, including antioxidant effects, modulation of mitochondrial function, neuroprotection, and potential influence on sarcopenic and osteopenic processes, although the clinical relevance of these non-energy mechanisms in older adults remains uncertain. As a nutritional supplement, creatine occupies a regulatory category distinct from prescription drugs, which has both accelerated population-level adoption and complicated the generation of conventional randomized-trial evidence at scale, because large long-duration outcome trials funded by industry are uncommon for non-patentable compounds. The clinical history of creatine is dominated by sports-medicine research, with thousands of participants studied in short-term resistance-training contexts, and only more recently has attention shifted to older adults, to patient populations, and to non-muscle endpoints such as cognition. This trajectory leaves the field with a substantial body of mechanistic and performance evidence but a comparatively thin evidence base for the aging endpoints that matter most to public health, a gap that the present synthesis is designed to help clarify.", "Despite the volume of creatine research, several unresolved questions remain central to any claim that creatine may influence healthspan or lifespan in older adults. First, the translation from acute bioenergetic and performance effects to sustained functional change in older adults has not been established, and the boundary between reversible metabolic effects and durable structural or cognitive benefits remains uncertain. Second, the literature shows clear population specificity: signals in young resistance-trained men, in older adults undergoing structured training, in patients with Alzheimer's disease, and in vegan or vegetarian cohorts may have different magnitudes and directions, and a unified mechanistic story has not yet been articulated. Third, dose-response relationships are incompletely characterized, with most trials using a small number of fixed protocols and limited head-to-head comparisons, so the question of whether higher or lower doses, different forms, or co-ingestion with related compounds produces incremental benefit is open. Fourth, the duration of supplementation in most trials remains short relative to the time horizons over which anti-aging benefits would plausibly accrue, raising the question of whether observed short-term changes in strength or muscle cross-sectional area translate into reduced falls, hospitalization, or disability over years. Fifth, the tradeoff between putative benefits and reported signals of harm or null effect in some outcome classes, including dietary-intake analyses suggesting a negative association with one context (Jiang 2025), demands careful separation of contexts in which creatine has been evaluated. Each of these gaps is consequential for clinical decision-making, and the present synthesis is structured to make these gaps visible rather than to smooth them over.", "This synthesis addresses the gap between mechanistic plausibility and clinical evidence for creatine as a candidate geroprotective intervention by explicitly separating direct from indirect evidence, clinical from mechanistic data, and concordant from discordant findings. Across the curated reference set, positive signals appear in muscle function and several contextual outcomes, while negative signals surface in distinct contexts, and null findings dominate large portions of the evidence base, producing cross-study disagreements that any responsible synthesis must acknowledge rather than resolve by averaging. The contribution of this work is therefore not a single pooled effect estimate but a structured weighting of evidence across outcome classes, populations, and study designs, with explicit attention to where direct interventional hard-endpoint evidence, indirect surrogate evidence, and preclinical mechanistic evidence can and cannot speak to the same question. By treating creatine as a context-dependent intervention whose effects vary with age, training status, baseline intake, and outcome domain, the synthesis aims to provide a more clinically useful map than either an unconditional endorsement or dismissal. The framework developed here may also serve as a template for evaluating other nutritional supplements proposed as geroscience candidates, and the resulting map should help clinicians, trialists, and funders identify the specific studies and populations most likely to change the current state of evidence in the coming years.", "Geroscience reframes chronic disease as the clinical expression of shared biological aging processes, with the hallmarks of aging (updated 2023) supplying a mechanistic vocabulary that links cellular decline to late-life morbidity. A central regulatory implication is that interventions capable of modifying one or more hallmarks — mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, loss of proteostasis, and the like — may plausibly delay or compress morbidity across organ systems, even when individual chronic diseases have not yet manifested. Creatine monohydrate sits naturally inside this framework: it buffers and regenerates ATP via the phosphocreatine system, and downstream effects on cellular energetics, redox balance, and protein turnover intersect with several hallmark axes. As regulatory bodies (e. For example, EFSA under Regulation (EC) No 1924/2006, per Turck 2024) increasingly evaluate structure/function claims against aging biology, the geroscience lens provides the conceptual scaffold within which a nutritional supplement candidate like creatine is judged. The present Background therefore sets up (i) the preclinical mechanisms by which creatine interfaces with aging biology, (ii) the human RCT evidence base, (iii) the registered-trial landscape, and (iv) the methodological questions that condition interpretation of that evidence.", "Several methodological and clinical-design questions condition the interpretability of the creatine evidence base. Second, surrogate-to-hard-outcome translation is uncertain — a caution explicitly raised by Ioannidis 2005 for any surrogate-endpoint-driven claim, and directly relevant to the use of psoas muscle ratio or D₃-creatine dilution as proxies for disability and mortality. Finally, concurrent interventions (resistance training in Amiri 2023, Wang 2024, Gu 2026, Liu 2025, Sharifian 2025; HMB in Ramos-Hernandez 2026; calorie restriction in Beavers 2023; eccentric loading in Yamaguchi 2025) are rarely constant, so isolated creatine effects are difficult to extract. The synthesis must therefore adjudicate not only whether creatine 'works' but under what boundary conditions — population, dose, duration, co-intervention, and endpoint — a signal emerges.", "Only a single contrast in the curated extracts reached the P < 0.001 threshold, while most markers clustered between P = 0.11 and P = 0.78 — a pattern consistent with mixed and largely null effects across muscle-damage surrogates. The accompanying p-values for the Effects of Short-Term Creatine 2024 review were not reported in the curated excerpts, so quantitative claims for that review are limited to its trial-level design features (Effects of Short-Term Creatine 2024).", "Mechanistically, the cardiometabolic outcome class in this corpus is populated by indirect evidence: the populations are healthy or athletic adults, not patients with cardiometabolic disease, and the endpoints are surrogate biomarkers of muscle damage and training adaptation rather than hard cardiovascular events (Doma 2022). The mechanistic substrate — phosphocreatine resynthesis, cell-volumization, and attenuated oxidative stress — is plausible from preclinical work but is not directly tested in any enrolled cardiometabolic cohort within the curated set (Doma 2022; Effects of Short-Term Creatine 2024). Accordingly, the human evidence speaks to exercise-physiology adaptations, while mechanistic transfer to cardiometabolic risk reduction remains a translational inference rather than a demonstrated RCT finding.", "The source does not disambiguate which p-value attaches to which contrast — for example, whether P = 0.02 or P = 0.03 corresponds to a cognition composite versus an individual NIH Toolbox subscore — so the prose references the evidence synthesis for the per-endpoint mapping rather than reattributing values. Against the integrating thesis that null findings dominate the corpus, Smith 2025b is consistent with that pattern in the cognitive domain, while still leaving room for mechanism-positive secondary endpoints.", "Because Smith 2025b is the only cognitive source, the within-corpus tension for this outcome class is one of sparsity rather than of disagreement: there is no second human RCT or observational cohort to contradict or replicate the null directional finding. The cross-study disagreement map confirms this, listing no non-orthogonal pairs for the cognitive outcome class. The integrating thesis is therefore consistent with the cognitive slice of the corpus — null findings dominate, mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and boundary conditions (dose, duration, disease stage) remain to be established in future trials.", "Mechanistically, the directly assessed clinical RCTs (Ramos-Hernandez 2026, Londono-Velasquez 2025) and the older-adult vascular pilot (Clarke 2024) point toward plausible functional and vascular substrates in trained or older populations, while the meta-analytic and review literature (Gu 2026) and the regulatory evaluation (Turck 2024) supply the broader, indirect contextual layer. By contrast, the large NHANES analytic cohort (Jiang 2025) frames a population-scale epidemiologic signal linking dietary creatine intake to cancer outcomes, and Desai 2025 contributes an intermediate-dose, mixed-sex resistance training randomised evaluation. Preclinical data and mechanistic human biomarker work converge on the principle that creatine augments phosphocreatine-driven ATP resynthesis and may influence endothelial and metabolic pathways, but the human evidence in this corpus is dominated by short-term, modest-sample, indirectness-tagged studies, with only Ramos-Hernandez 2026 and Londono-Velasquez 2025 carrying direct-design labels for the outcomes they tested. The mechanistic substrate underlying the contextual findings therefore remains anchored to small, targeted, often crossover designs rather than long-horizon outcome trials.", "Across the corpus, within-domain tensions are most visible on muscle function. Agreement clusters around Davies 2023 with Tam 2025 and Amiri 2023 with Tam 2025 on positive direction. The likely mechanistic explanation is a gene-by-supplementation interaction: Varillas-Delgado 2024 explicitly stratifies by genetic profile, and certain genotypes may blunt or even reverse the typical phosphocreatine-loading response, whereas Davies 2023 and Amiri 2023 pool across genotypes and dilute any signal in either direction. The boundary condition is therefore population-genetic: aggregate positive evidence applies to genetically unselected resistance-training cohorts, while negative evidence applies to the subset of professional athletes whose genotype does not support creatine-driven hypertrophy. What would resolve this tension is an adequately powered, genotype-stratified RCT comparing creatine versus placebo on lean mass and strength, with the genetic stratification pre-specified rather than post hoc; until such a trial is reported, the two literatures can be interpreted as complementary rather than contradictory, each applying to its own population."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "20c54f16-9fa0-483f-a812-d305b4b1d813", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 28, "included": 28, "included_or_retained": 28, "screened": 28, "wording": "28 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "20c54f16-9fa0-483f-a812-d305b4b1d813",
  "researka_submission_id": "7bff8453-a2c4-40a0-b1f6-deb5803d948d",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/20c54f16-9fa0-483f-a812-d305b4b1d813/sidecars/contradiction_map.json"
}